Pricing its initial public offering at CHF18 per share - the bottom of its expected range of CHF18 to CHF22 - Arpida AG realized gross proceeds of CHF97.2 million (US$80.9 million) from its debut on the Swiss Stock Exchange May 4. (BioWorld International) Read More
